Skip to main content
. 2017 Nov 14;118(1):138–144. doi: 10.1038/bjc.2017.371

Table 1. The characteristics of the two study populations.

  CSi (N=23632)
Horizon (N=3347)
  CSi-attenders (n=4865) GP-attenders (n=4291) Non-responders (n=14476) GP-taken sample (n=3347)
Mean age (years; 95% CI) 47.1 (46.8–47.5) 40.3 (40.0–40.6) 47.6 (47.4–47.8) 40.6 (40.3–41.0)
Age group (years)                
 27–29 385 7.9% 588 13.7% 1318 9.1% 478 14.3%
 30–39 1092 22.4% 1657 38.6% 2962 20.5% 1295 38.7%
 40–49 1215 25.0% 1311 30.6% 3107 21.5% 897 26.8%
50–59 1275 26.2% 514 12.0% 4099 28.3% 462 13.8%
 60–65 898 18.5% 221 5.1% 2990 20.7% 215 6.4%
 Total 4865 100.0% 4291 100.0% 14 476 100.0% 3347 100.0%
Screening historya                
 Long-term unscreened 1621 39.9% 927 30.8% 7540 64.0% 133 5.8%
 Intermittently screened 2440 60.1% 2083 69.2% 4243 36.0% 2158 94.2%
 Total 4061 100.0% 3010 100.0% 11 783 100.0% 2291 100.0%
Histology (regardless of the HPV test result)                
 Normal 134 47.3% 188 57.8% 47 78.3% 206 56.3%
 CIN1 45 15.9% 30 9.2% 1 1.7% 44 12.0%
 CIN2 22 7.8% 23 7.1% 0 0.0% 24 6.6%
 CIN3 76 26.9% 76 23.4% 6 10.0% 61 16.7%
 Cervical cancer 5 1.8% 7 2.2% 6 10.0% 1 0.3%
 Inadequate material 1 0.4% 1 0.3% 0 0.0% 30 8.2%
 Total 283 100.0% 325 100.0% 60 100.0% 366 100.0%
⩾CIN2 detection (regardless of the HPV test result)                
 <CIN2 179 63.5% 218 67.3% 48 80.0% 250 74.4%
 ⩾CIN2 (positive predictive value) 103 36.5% 106 32.7% 12 20.0% 86 25.6%
 Total 282 100.0% 324 100.0% 60 100.0% 336 100.0%
Positive predictive value of ⩾CIN2 detection compared with Horizon P<0.01 P=0.02 P=0.93 Reference

Abbreviations: CI=confidence interval; CIN=cervical intraepithelial neoplasia; GP=general practitioner; HPV=human papillomavirus; Intermittently screened=cytology sample registered within the past 10 years (though not in the last screening round, see eligibility criteria); Long-term unscreened=no cytology sample registered in the past 10 years.

a

Restricted to women aged ⩾34 years, N=21 145 for both studies combined. These women have been recommended for screening for at least 10 years.